We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
MedicalSystem

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests

By LabMedica International staff writers
Posted on 07 Nov 2022
Print article
Image: Numares AXINON System (Photo courtesy of Numares)
Image: Numares AXINON System (Photo courtesy of Numares)

An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.

The expanded collaboration builds on Mayo Clinic’s (Rochester, MN, USA) clinical research support for Numares Health (Regensburg, Germany) to include an innovative convertible equity investment. Numares is a health care company using AI-enabled technology to develop novel diagnostic tests designed to give physicians a better tool to care for their patients with conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases. These assessments also may allow for early intervention to slow disease progression. Enabled by machine learning, this innovative testing modality being researched uses distinct and transparent algorithms combining multiple biomarkers to measure disease progression more accurately in patients with chronic diseases.

Numares develops advanced tests to aid in diagnosis and measurement of disease progression by applying machine learning to metabolomics and other biomarkers. The company has developed the AXINON System that uses next-generation nuclear magnetic resonance spectroscopy to evaluate metabolic constellations and a proprietary magnetic group signaling (MGS) technology that enables the spectroscopy. Two Numares tests are expected to gain FDA 510(k) approval early next year, one assessing kidney function (AXINON GFR(NMR) test) and one measuring cardiac risk (AXINON lipoFIT test).

"The expanded research collaboration and financial investment in Numares will help us further understand this new and potentially disruptive test modality, develop new diagnostic tests and enable Mayo Clinic to better serve our patients and physicians," said Dr. Allan Jaffe, a cardiologist and the former chair of Mayo Clinic's division of clinical core laboratory services in the department of laboratory medicine and pathology.

"This significant expansion of our long-standing collaboration with Mayo Clinic has brought us one step closer to our shared goal of improving patient care," said Winton Gibbons, Numares chief executive officer. "The new investment accelerates our development pipeline and drives research collaborations that fulfill critical unmet medical needs with new clinical utility. With the additional investment, we've enhanced our ability to target our focus on delivering this patient care technology to U.S. physicians as an improved diagnostic tool for their use."

Related Links:
Mayo Clinic 
Numares Health 

Gold Supplier
Hematology Workflow Solution
DIFF-Line
New
POC Molecular Diagnostics Analysis System
ClariLight CL30
New
Plastic Jerricans
Diamond RealSeal Jerricans
New
Antimicrobial Susceptibility Testing Software
MICRONAUT6 Software

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: Equivalence of Genetically Elevated LDL and Lipoprotein(a) on Myocardial Infarction (Photo courtesy of Viborg Regional Hospital)

Familial Hypercholesterolemia Patients With ACD Have Elevated Lipoprotein(a)

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL cholesterol), in the blood and early cardiovascular... Read more

Molecular Diagnostics

view channel
Image: A cheap blood test could improve diagnosis of myocarditis (Photo courtesy of Queen Mary University of London)

First-Ever Blood Test Could Detect Deadly Heart Inflammation Within Hours

Myocarditis, or inflammation of the heart muscle, is a difficult condition to diagnose. Symptoms include a temperature, fatigue, chest pain and shortness of breath, which can all be easily mistaken for... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.